Frontiers in Aging Neuroscience,
Journal Year:
2019,
Volume and Issue:
11
Published: Dec. 11, 2019
Post-stroke
systemic
injections
of
insulin-like
growth
factor
1
(IGF-1)
exert
neuroprotective
effects
in
rats.
In
the
current
study,
we
aimed
to
test
efficacy
IGF-1
neuroprotection
aged
rats
(24-25
months
old)
and
compare
results
with
adult
(6-7
old).
Furthermore,
addressed
putative
differences
microglial
responses
Rats
were
subjected
ischemic
stroke
while
they
conscious
by
infusing
endothelin-1
(Et-1)
through
a
guide
cannula
that
was
implemented
vicinity
middle
cerebral
artery
(MCA).
given
subcutaneous
(1
mg/kg)
at
30
min
120
after
insult.
treatment
reduced
infarct
size
34%
38%
rats,
respectively.
The
treated
also
showed
significant
improvement
sensorimotor
function
following
stroke,
this
not
significantly
affected
displayed
exaggerated
activation
microglia
hemisphere.
Significant
reduction
only
detected
specific
regions
ipsilateral
hemisphere
We
show
an
stroke.
It
remains
be
established,
however,
whether
age-related
changes
affect
behavioral
outcome.
Stem Cell Research & Therapy,
Journal Year:
2020,
Volume and Issue:
11(1)
Published: Jan. 21, 2020
Mesenchymal
stem
cells
(MSCs)
hold
great
potential
as
a
therapy
for
stroke
and
have
previously
been
shown
to
promote
recovery
in
preclinical
models
of
cerebral
ischaemia.
MSCs
secrete
wide
range
growth
factors,
chemokines,
cytokines
extracellular
vesicles-collectively
termed
the
secretome.
In
this
study,
we
assessed
first
time
efficacy
IL-1α-primed
MSC-derived
secretome
on
brain
injury
functional
after
ischaemia.Stroke
was
induced
male
C57BL/6
mice
using
intraluminal
filament
model
middle
artery
occlusion.
Conditioned
medium
from
or
vehicle
administered
at
reperfusion
24
h
post-stroke
by
subcutaneous
injection.IL-1α-primed
conditioned
treatment
led
~
30%
reduction
lesion
volume
48
associated
with
modest
improvements
body
mass
gain,
28-point
neurological
score
nest
building.
Administration
improved
building
despite
no
observed
differences
day
2
post-stroke.Our
results
show
that
administration
leads
behavioural
outcomes
independently
neuroprotection.
Journal of Cerebral Blood Flow & Metabolism,
Journal Year:
2021,
Volume and Issue:
41(9), P. 2439 - 2455
Published: March 28, 2021
There
is
emerging
evidence
suggesting
that
a
cortical
stroke
can
cause
delayed
and
remote
hippocampal
dysregulation,
leading
to
cognitive
impairment.
In
this
study,
we
aimed
investigate
motor
outcomes
after
experimental
stroke,
their
association
with
secondary
neurodegenerative
processes.
Specifically,
used
photothrombotic
model
targeting
the
somatosensory
cortices
of
mice.
Motor
function
was
assessed
using
cylinder
grid
walk
tasks.
Changes
in
cognition
were
mouse
touchscreen
platform.
Neuronal
loss,
gliosis
amyloid-β
accumulation
investigated
peri-infarct
ipsilateral
regions
at
7,
28
84
days
post-stroke.
Our
findings
showed
persistent
impairment
post-stroke,
whilst
there
modest
spontaneous
recovery
over
period
days.
region,
detected
reduction
neuronal
loss
decreased
neuroinflammation
time
which
potentially
explains
recovery.
Conversely,
observed
together
concomitant
increased
hippocampus,
likely
accounts
for
dysfunction.
indicate
induces
processes
region
from
primary
infarct,
contributing
progression
post-stroke
Biomedicines,
Journal Year:
2021,
Volume and Issue:
9(7), P. 703 - 703
Published: June 22, 2021
Ischemic
stroke
is
caused
by
a
thromboembolic
occlusion
of
major
cerebral
artery,
with
the
impaired
blood
flow
triggering
neuroinflammation
and
subsequent
neuronal
damage.
Both
innate
immune
system
(e.g.,
neutrophils,
monocytes/macrophages)
in
acute
ischemic
phase
adaptive
T
cells,
B
cells)
chronic
contribute
to
this
neuroinflammatory
process.
Considering
that
available
therapeutic
strategies
are
insufficiently
successful,
there
an
urgent
need
for
novel
treatment
options.
It
has
been
shown
increasing
cAMP
levels
lowers
neuroinflammation.
By
inhibiting
cAMP-specific
phosphodiesterases
(PDEs),
i.e.,
PDE4,
7,
8,
can
be
tempered
through
elevating
and,
thereby,
induce
improved
functional
recovery.
This
review
discusses
recent
preclinical
findings,
clinical
implications,
future
perspectives
PDE
inhibition
as
research
interest
stroke.
In
particular,
PDE4
extensively
studied,
promising
following
stroke,
whereas
PDE7
8
more
target
cell
component.
addition,
targeted
gene
inhibition,
or
combined
requires
extensive
research.
Progress in Neurobiology,
Journal Year:
2021,
Volume and Issue:
209, P. 102199 - 102199
Published: Dec. 16, 2021
Restoration
of
functional
connectivity
is
a
major
contributor
to
recovery
after
stroke.
We
investigated
the
role
reactive
astrocytes
in
and
photothrombotic
stroke
mice
with
attenuated
gliosis
(GFAP–/–Vim–/–).
Infarct
volume
longitudinal
changes
were
determined
by
vivo
T2-weighted
magnetic
resonance
imaging
(MRI)
resting-state
MRI.
Sensorimotor
function
was
assessed
behavioral
tests,
glial
neural
plasticity
responses
quantified
peri-infarct
region.
Four
weeks
stroke,
GFAP–/–Vim–/–
showed
impaired
sensorimotor
aberrant
restoration
global
neuronal
connectivity.
These
also
exhibited
maladaptive
responses,
shown
higher
number
lost
newly
formed
connections
between
primary
secondary
targets
cortical
regions
increased
expression
axonal
marker
Gap43.
conclude
that
modulate
recovery-promoting
ischemic
Journal of Cerebral Blood Flow & Metabolism,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 20, 2025
Stroke-associated
mood
disorders
are
less
recognised
than
sensorimotor
impairment,
despite
their
high
prevalence.
Similarly,
few
experimental
stroke
studies
assess
non-sensorimotor
functions.
This
study
examined
the
prevalence
and
implementation
of
tests
in
three
stroke-focused
journals
over
last
twenty
years.
Of
965
ischaemic
papers
which
used
behavioural
testing
rodents,
932
included
testing,
while
137
(most
commonly
Morris
water
maze,
open
field,
Y-maze,
novel
object
recognition
tests,
but
with
a
more
diverse
range
introduced
recent
years).
Cognition,
anxiety
depression
were
assessed
70%,
27%
3%
these
papers.
Non-sensorimotor
deficits
typically
observed
after
recovery
function.
Potential
confounding
factors
challenges
for
data
interpretation
identified
most
prevalent
tests.
More
generally,
rigor
(a
priori
power
calculation,
randomisation,
blinding,
pre-defined
inclusion/exclusion)
improved
years,
remained
unsatisfactory
only
26%
providing
some
evidence
adequate
statistical
power.
Furthermore,
focused
on
male
animals,
limiting
external
validity.
review
confirms
disparity
between
shows
that
share
including
latter
is
increasing.
It
essential
research
into
neuropsychiatric
sequalae
addresses
methodological
issues
noted
continues
to
expand
improve
patient
outcomes
post-stroke.
Neurorehabilitation and neural repair,
Journal Year:
2018,
Volume and Issue:
33(1), P. 27 - 37
Published: Dec. 10, 2018
Background.
Stroke
is
a
leading
cause
of
neurological
disability,
often
resulting
in
long-term
motor
impairments
due
to
damage
cortical
or
subcortical
areas.
Despite
the
high
prevalence
strokes
clinical
population,
preclinical
research
has
primarily
focused
on
investigating
and
treating
strokes.
Moreover,
while
both
humans
animals
show
spontaneous
recovery
following
stroke,
little
known
about
how
injury
location
affects
this
process.
Objective.
To
capture
heterogeneity
human
stroke
examine
cortical,
subcortical,
combination
Methods.
Endothelin-1
(ET-1),
potent
vasoconstrictor,
was
used
produce
focal
infarcts
forelimb
cortex
(FMC),
dorsolateral
striatum
(DLS)
FMC
DLS
male
Sprague-Dawley
rats.
The
profile
followed
over
an
8-week
period
using
battery
behavioral
tasks
assessing
function
limb
preference.
Results.
All
3
groups
showed
significant
Montoya
staircase,
beam,
cylinder
tests
with
combined
group
(FMC
+
DLS)
having
largest
most
persistent
impairments.
Importantly,
not
simply
dependent
lesion
volume,
but
location,
test
employed.
Conclusions.
markedly
differentially
influences
level
functional
recovery,
which
only
captured
by
multiple
outcome
measures.
These
results
illustrate
need
for
models
align
especially
respect
size,
Journal of Cerebral Blood Flow & Metabolism,
Journal Year:
2019,
Volume and Issue:
39(12), P. 2323 - 2342
Published: Sept. 14, 2019
Novel
therapeutic
intervention
that
aims
to
enhance
the
endogenous
recovery
potential
of
brain
during
subacute
phase
stroke
has
produced
promising
results.
The
paradigm
shift
in
treatment
approaches
presents
new
challenges
preclinical
and
clinical
researchers
alike,
especially
functional
endpoints
domain.
Shortcomings
“neuroprotection”
era
research
are
yet
be
fully
addressed.
Proportional
observed
clinics,
potentially
animal
models,
requires
a
thorough
reevaluation
methods
used
assess
recovery.
To
this
end,
review
give
detailed
evaluation
outcome
measures
clinics
studies.
Impairments
models
will
discussed
from
testing
perspective.
Approaches
needed
bridge
gap
between
research,
along
with
means
measure
moving
target
recovery,
discussed.
Concepts
such
as
true
function
compensation
suitable
for
distinguishing
two
examined.
Often-neglected
outcomes
stroke,
emotional
disturbances,
draw
attention
need
further
area.
Frontiers in Cell and Developmental Biology,
Journal Year:
2020,
Volume and Issue:
8
Published: Oct. 30, 2020
Olfactory
mucosa
mesenchymal
stem
cells
(OM-MSCs)
have
exhibited
their
effectiveness
in
central
nervous
system
diseases
and
provided
an
appealing
candidate
for
the
treatment
of
ischemic
stroke.
Previous
evidence
showed
that
Golgi
apparatus
(GA)
secretory-pathway
Ca2+-transport
ATPases
isoform1
(SPCA1)
was
a
potential
therapeutic
target
In
this
study,
we
explored
neuroprotective
mechanism
OM-MSCs
its
effect
on
expression
function
SPCA1
during
cerebral
ischemia/reperfusion.
Based
vitro
vivo
experiments,
discovered
attenuated
apoptosis
oxidative
stress
stroke
models,
reduced
infarction
volume
improved
neurologic
deficits
rats.
also
upregulated
alleviated
Ca2+
overload,
decreased
edema
dissolution
GA
neurons.
Moreover,
depletion
OGD/R
treated
N2a
mitigated
protective
effects
OM-MSCs.
Altogether,
exerted
probably
via
modulating
reducing